Article Text

Download PDFPDF
Original research
Tracking missed opportunities for an early HIV diagnosis in a population of people living with HIV with known time of infection
  1. Dimitrios Basoulis1,
  2. Evangelia Georgia Kostaki2,
  3. Dimitrios Paraskevis2,
  4. Angelos Hatzakis2,
  5. Mina Psichogiou1
  1. 1 1st Internal Medicine Department, Laiko General Hospital, National and Kapodistrian University of Athens, Athens, Attica, Greece
  2. 2 Department of Hygiene, Epidemiology and Medical Statistics, National and Kapodistrian University of Athens School of Health Sciences, Athens, Greece
  1. Correspondence to Dr Dimitrios Basoulis, 1st Internal Medicine Department, Laiko General Hospital, National and Kapodistrian University of Athens, Athens, Attica, Greece; dimitris.bassoulis{at}gmail.com

Abstract

Purpose The goal of 90-90-90 first requires the expansion of access to HIV testing. Our aim was to record frequencies of HIV indicator conditions (ICs) and identify missed opportunities for an early HIV diagnosis.

Methods We retrospectively identified ICs in a population of 231 people living with HIV with known infection dates who attended our clinic. The study population was divided into four groups: (1) those self-tested pre-emptively (47/231, 20.3%), (2) those offered targeted testing based on risk factors (67/231, 29%), (3) those tested after an IC (73/231, 31.6%) and (4) those who were not offered testing after an IC (44/231, 19%). HIV acquisition dates were estimated by molecular clock analysis.

Results A total of 169 healthcare contacts (HCCs) were recorded. The most frequent HCC was mononucleosis-like syndrome (20.1%), unexplained weight loss (10.7%) and STIs (10.1%). AIDS-defining conditions were detected in 11.8%. Only 62.4% (73/117) of those with an IC were offered testing after their first HCC. Patients in group 4 had statistically significant delay in diagnosis compared with group 3 (109.1 weeks (IQR 56.4–238.6) vs 71.6 weeks (IQR 32.3–124.6)). The proportion of patients diagnosed as late presenters in each group was: (1) 16/47 (34%), (2) 37/67 (55.2%), (3) 43/73 (58.9%) and (4) 27/44 (61.4%) (p=0.027).

Conclusions Our study uses a combination of molecular and clinical data and shows evidence that late presentation occurs in a high proportion of patients even in the presence of an IC. Given that risk-based targeted testing has low coverage, IC-guided testing provides a reasonable alternative to facilitate earlier HIV diagnosis and to improve late diagnosis across Europe and globally.

  • diagnosis
  • epidemiology (molecular)
  • epidemiology (clinical)
  • HIV clinical care
  • testing

Data availability statement

Data are available at the National and Kapodistrian University of Athens repository, "Pergamos" (https://pergamos.lib.uoa.gr/uoa/dl/object/2934905).

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available at the National and Kapodistrian University of Athens repository, "Pergamos" (https://pergamos.lib.uoa.gr/uoa/dl/object/2934905).

View Full Text

Footnotes

  • Handling editor Francesca Ceccherini-Silberstein

  • Presented at 20th Panhellenic Infectious Diseases Conference, 5–8 March 2020, Athens, Greece; 30th ECCMID, 18–21 April, Paris, France.

  • Contributors DB performed clinical data collection, statistical analysis and authored the manuscript, EGK and DP performed molecular clock analysis and reviewed the manuscript, AH assisted in statistical analysis, aided in interpreting results, reviewed the manuscript, MP had the original concept and designed the study, reviewed the manuscript and had final supervision.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.